Cargando…
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. METHODS:...
Autores principales: | Gu, Ha Ra, Park, Su Cheol, Choi, Su Jin, Lee, Jae Cheol, Kim, You Cheoul, Han, Chul Ju, Kim, Jin, Yang, Ki Young, Kim, Yeon Joo, Noh, Geum Youb, No, So Hyeon, Jeong, Jae-Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379197/ https://www.ncbi.nlm.nih.gov/pubmed/25834802 http://dx.doi.org/10.3350/cmh.2015.21.1.49 |
Ejemplares similares
-
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021) -
Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015) -
Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2022) -
Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019) -
Clinical and Radiologic Outcomes of Small Glenoid Baseplate in Reverse Total Shoulder Arthroplasty: A Prospective Multicenter Study
por: Kim, Min-Su, et al.
Publicado: (2022)